Oncolys BioPharma
Oncolys BioPharma is a Tokyo-based clinical-stage and newly commercial Japanese biopharma developing telomerase-specific oncolytic adenovirus therapies and virus-based cancer diagnostics. Its lead product, Telomelysin (OBP-301), received Japan PMDA approval in June 2026 for esophageal cancer, commercialized via FUJIFILM Toyama Chemical.
- Company typePublic
- Founded2004
- HeadquartersTokyo, Japan
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Oncolys BioPharma does
Oncolys BioPharma Inc. is a Tokyo-headquartered, publicly-traded Japanese biopharmaceutical company (TSE Growth Market: 4588) founded in 2004 by Yasuo Urata, focused on the discovery, development, and commercialization of oncolytic virus therapies and virus-based diagnostics for cancer. The company's proprietary platform is built on telomerase-specific replication-competent adenovirus type 5 technology, which selectively replicates in and lyses cancer cells while sparing normal tissue due to low telomerase activity in healthy cells. Its lead asset, OBP-301 (suratadenoturev, brand name Telomelysin), received standard manufacturing and marketing approval from Japan's MHLW in June 2026 for the treatment of unresectable esophageal cancer — making it Japan's first approved oncolytic adenovirus therapy and the company's first commercial product. The pipeline extends across next-generation oncolytic viruses (OBP-702, armed with p53 for 10-30x stronger anti-tumor activity), cancer diagnostics (OBP-401/OBP-1101 Telomescan for circulating tumor cell detection), antivirals (OBP-601/Censavudine for neurodegenerative disease via LINE-1 inhibition, licensed to Transposon Therapeutics; OBP-2011 for COVID-19 via nucleocapsid inhibition), and a repositioned HDAC inhibitor (OBP-801, now in ophthalmology research).
The company operates a hybrid revenue model combining licensing/royalty income from out-licensed assets (notably the $300M+ Transposon deal for OBP-601) with co-promotion product sales following the Telomelysin approval. Commercial distribution in Japan is handled exclusively by FUJIFILM Toyama Chemical under a February 2024 sales partnership that provides hospital access, promotional infrastructure, and NHI pricing negotiation support. R&D is anchored at the Kobe Research Lab on Port Island, with wholly-owned US subsidiaries (Oncolys USA Inc. in Delaware since 2016 and OPA Therapeutics Inc. in California since 2020) supporting US licensing and next-generation development. End customers are healthcare institutions and oncologists at major cancer centers in Japan, with clinical research collaborations spanning Okayama University, National Cancer Center East, Juntendo University, and Kagoshima University. Customer concentration is high by virtue of single-partner commercial distribution and a single-counterparty licensing deal; the company has 11-50 employees, a founder-CEO-led management team, and a previously disclosed substantial cash position supporting the post-launch commercial and pipeline expansion phase.
Oncolys BioPharma firmographics
Firmographics- Name
- Oncolys BioPharma
- Legal name
- オンコリスバイオファーマ株式会社
- Website
- https://oncolys.com
- Company type
- Public
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Oncolys BioPharma is a Tokyo-based clinical-stage and newly commercial Japanese biopharma developing telomerase-specific oncolytic adenovirus therapies and virus-based cancer diagnostics. Its lead product, Telomelysin (OBP-301), received Japan PMDA approval in June 2026 for esophageal cancer, commercialized via FUJIFILM Toyama Chemical.
- Ownership category
- akta.pro rank
Oncolys BioPharma industry classification
Industry- Product category
- Cancer Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)
- akta.pro secondary industry
- Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)
Keywords
Where Oncolys BioPharma is headquartered
LocationHeadquarters
- HQ city
- Tokyo
- HQ country
- Japan
- HQ region
- Asia
Offices3 records
Markets served
Oncolys BioPharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Licensing Revenue: Contract-based licensing model where Oncolys develops compounds to certain stages and partners with pharmaceutical companies for remaining development and commercialization. Receives milestone payments tied to development progress and royalty payments based on product sales.
- Product Sales: Following OBP-301 approval, the company transitioned from pure licensing to a hybrid model including direct product sales through co-promotion with Fujifilm Toyama Chemical.
- Collaboration Revenue: Revenue from co-development arrangements including development support payments and research collaborations with academic institutions and pharmaceutical partners.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Oncolys BioPharma product offering
Product offeringCore offering
Oncolys BioPharma develops virus-based therapeutics and diagnostics for cancer and serious viral diseases. Its lead marketed product, Telomelysin (OBP-301, generic suratadenoturev), is Japan's first approved oncolytic adenovirus therapy, indicated for esophageal cancer. The company also maintains a pipeline of next-generation oncolytic viruses (OBP-702), cancer detection viruses (OBP-401/OBP-1101 Telomescan), an HDAC inhibitor (OBP-801), and antiviral candidates (OBP-601 Censavudine, OBP-2011).
Product overview
Oncolys BioPharma is a biopharmaceutical company developing virus-based therapeutics and diagnostics. The company operates two core platforms: oncolytic virus therapy for cancer treatment (OBP-301, OBP-702) and antiviral drugs for severe viral infections (OBP-601, OBP-2011), plus cancer diagnostic tests (OBP-401, OBP-1101). Telomelysin®注 (OBP-301) received manufacturing and marketing approval in June 2026 as Japan's first oncolytic adenovirus therapy for esophageal cancer.
Differentiator
Problem solved
Functional benefit
Brands
- Telomelysin (テロメライシン): OBP-301 oncolytic virus therapy product for esophageal cancer treatment, approved in Japan in June 2026
- Telomescan (テロメスキャン)
- OBP-301
Products and services
- Telomelysin Injection (OBP-301, suratadenoturev) Approved injectable oncolytic adenovirus therapy for the treatment of unresectable esophageal cancer in combination with radiation therapy. The first oncolytic adenovirus therapy approved in Japan; sold to hospitals and cancer centers through Fujifilm Toyama Chemical's distribution network.
- Telomescan (OBP-401 / OBP-1101) Cancer diagnostic test using telomerase-specific adenovirus carrying a fluorescent reporter gene (GFP) or engineered fiber to detect circulating tumor cells (CTCs) in blood samples. Intended for cancer detection and liquid biopsy applications in research and clinical settings.
Quantifiable outcome
- Phase 2 trials showed approximately 60% local complete response rate for esophageal cancer with OBP-301 + radiation combination, compared to ~30% with radiation alone
- +2 more outcomes
Companies that use Oncolys BioPharma
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
Oncolys BioPharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Oncolys BioPharma partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Fujifilm Toyama Chemical Co., Ltd.coreFujifilm Toyama Chemical serves as the sales promotion partner for Telomelysin (OBP-301) in Japan following June 2026 approval. The partnership involves co-promotion activities including promotional material development, hospital procurement negotiations, launch symposiums, and nationwide product distribution.
- Transposon Therapeutics, Inc.coreLicensed OBP-601 (Censavudine/TPN-101) worldwide with sublicense rights for neurological diseases including PSP, ALS, and FTD. Deal valued at over $300 million USD in upfront and milestone payments plus royalties. Transposon, backed by venture capital and Brown University technology, funds all development costs.
- Kagoshima UniversitycorePatent transfer agreement for OBP-2011 coronavirus treatment development. Long-standing collaboration on antiviral drug development including HIV, HCV, and HBV with Prof. Masanori Baba's Retrovirus Research Center.
- OPA Therapeutics Inc.minorWholly-owned subsidiary established in California for third-generation oncolytic virus development and West Coast biotech operations.
- Chugai Pharmaceutical Co., Ltd.minorExclusive licensing partnership for OBP-301 in Japan and Taiwan with option rights, signed in April 2019. Partnership concluded in October 2021 with development rights returned to Oncolys BioPharma. During partnership, Chugai conducted Phase 2 trials and bore development costs.
- Juntendo UniversitycoreJoint research collaboration for OBP-401/OBP-1101 practical application focusing on circulating tumor cell (CTC) detection and cancer liquid biopsy applications. Established collaborative research department within the university.
- Oncolys USA Inc.coreWholly-owned US subsidiary established in Delaware to accelerate licensing activities and clinical development in North America. Operates from New Jersey area.
- Astellas Pharma Inc.minorLicensed OBP-801 (HDAC inhibitor) worldwide from Astellas Pharma for development as a novel molecular targeted anticancer agent. Company received capital participation from Astellas.
- Medigen Biotechnology Corp. (Taiwan)minorStrategic partnership for OBP-301 development and commercialization in Taiwan and related markets.
Scale indicators7 records
Recent moves9 records
Expansion highlights5 records
Oncolys BioPharma competitors and assessment
Company assessmentDirect peers
- PsiOxus Therapeutics: PsiOxus develops enadenotucirev, an oncolytic adenovirus platform (now called ngly1) being tested in multiple solid tumor indications including in combination with checkpoint inhibitors. It is a direct peer to Oncolys in the oncolytic adenovirus space targeting solid tumors.
- Amgen: Amgen commercializes Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy (for melanoma). It is the most directly comparable commercial-stage oncolytic virus company globally and a critical reference point for Telomelysin's launch trajectory, pricing, and physician adoption patterns.
- Vyriad: Vyriad develops oncolytic vesicular stomatitis virus (VSV) and measles virus platforms for solid tumors, including combination therapy programs with checkpoint inhibitors. It is comparable as a clinical-stage oncolytic virus developer focused on solid tumor immunotherapy.
- DNAtrix: DNAtrix develops DNX-2401 (tasadenoturev), an oncolytic adenovirus for glioblastoma and other solid tumors, using a tumor-selective adenovirus platform that closely parallels Oncolys's telomerase-targeted approach.
- Turnstone Biologics: Turnstone Biologics develops oncolytic virus immunotherapies (including the Seprehvir/hVIP combination platform) for solid tumors, with active clinical programs in combination with checkpoint inhibitors. It is a peer in the oncolytic virus + immune checkpoint combination space.
- Sorrento Therapeutics: Sorrento has pursued multiple oncology platforms including oncolytic virus programs and cellular therapies, positioning it as a broad peer in the virus-based cancer treatment space relevant to Oncolys's pipeline.
- Genelux Corporation: Genelux is a clinical-stage oncolytic virus company developing GL-ONC1 (Olvi-Vec) and other vaccinia- and adenovirus-based candidates for solid tumor treatment. Like Oncolys, it uses genetically modified viruses to selectively replicate in and destroy cancer cells.
- Lokon Pharma: Lokon Pharma develops the LOAd (Locked-On Adenovirus) platform of oncolytic adenoviruses armed with immunostimulatory transgenes for cancer treatment, directly comparable to Oncolys's OBP-702 next-generation p53-armed adenovirus platform.
Broad incumbents
- Daiichi Sankyo: Daiichi Sankyo is a major Japanese pharmaceutical company with significant oncology franchises and ADC platform leadership (Enhertu). It is comparable to Oncolys as a Japan-headquartered oncology drug developer, but at a vastly larger scale and broader portfolio.
- Astellas Pharma: Astellas is a global Japanese pharmaceutical company and an existing Oncolys partner (licensed OBP-801 to Oncolys and holds 2.48% equity). It represents a comparable large Japanese pharma with broad oncology and specialty therapeutics franchises, and a potential strategic acquirer or commercialization partner.
Market position
Strengths1 record
Weaknesses1 record
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Oncolys BioPharma social profiles
Digital presenceOncolys BioPharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oncolys BioPharma leadership team
Management profileNumber of profiles
Profiles5 records
Oncolys BioPharma subsidiaries and ownership
Company hierarchySubsidiaries2 records
Oncolys BioPharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oncolys BioPharma M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oncolys BioPharma
What does Oncolys BioPharma do?
Oncolys BioPharma develops virus-based therapeutics and diagnostics for cancer and serious viral diseases. Its lead marketed product, Telomelysin (OBP-301, generic suratadenoturev), is Japan's first approved oncolytic adenovirus therapy, indicated for esophageal cancer. The company also maintains a pipeline of next-generation oncolytic viruses (OBP-702), cancer detection viruses (OBP-401/OBP-1101 Telomescan), an HDAC inhibitor (OBP-801), and antiviral candidates (OBP-601 Censavudine, OBP-2011).
Is Oncolys BioPharma a public or private company?
Oncolys BioPharma is a public company. It is classified as public and is currently operating.
When was Oncolys BioPharma founded?
Oncolys BioPharma was founded in 2004. It employs 11 to 50 people.
Where is Oncolys BioPharma based?
Oncolys BioPharma is headquartered in Tokyo, Japan, in the Asia region.
How does Oncolys BioPharma make money?
Three revenue lines are on record. Licensing Revenue is the primary driver. The others are product Sales and collaboration Revenue.
Who are Oncolys BioPharma's main competitors?
Direct peers on record are PsiOxus Therapeutics, Amgen, Vyriad, DNAtrix, Turnstone Biologics, Sorrento Therapeutics, Genelux Corporation and Lokon Pharma. Broad incumbents are Daiichi Sankyo and Astellas Pharma.
Does Oncolys BioPharma have an API?
No public API is recorded for Oncolys BioPharma.
What industry is Oncolys BioPharma in?
Oncolys BioPharma's product category is Cancer Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2836.